

# Davide Corti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5170634/publications.pdf>

Version: 2024-02-01

92  
papers

24,038  
citations

22132

59  
h-index

51562

86  
g-index

129  
all docs

129  
docs citations

129  
times ranked

24900  
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. <i>Cell</i> , 2022, 185, 872-880.e3.	13.5	165
2	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. <i>Science</i> , 2022, 375, 449-454.	6.0	108
3	Predicting the mutational drivers of future SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2022, 14, eabk3445.	5.8	101
4	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 490-495.	15.2	577
5	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. <i>Nature</i> , 2022, 603, 706-714.	13.7	756
6	Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. <i>PLoS ONE</i> , 2022, 17, e0263328.	1.1	21
7	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. <i>PLoS Pathogens</i> , 2022, 18, e1010248.	2.1	48
8	Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy. <i>Current Opinion in Virology</i> , 2022, 53, 101204.	2.6	21
9	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> , 2022, 602, 664-670.	13.7	917
10	Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. <i>Science</i> , 2022, 375, 864-868.	6.0	394
11	Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein. <i>Cell</i> , 2022, 185, 2279-2291.e17.	13.5	25
12	Structure of the rabies virus glycoprotein trimer bound to a prefusion-specific neutralizing antibody. <i>Science Advances</i> , 2022, 8, .	4.7	16
13	Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution. <i>Science</i> , 2022, 377, 420-424.	6.0	140
14	Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. <i>Nature Communications</i> , 2022, 13, .	5.8	93
15	ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. <i>Science</i> , 2022, 377, 735-742.	6.0	85
16	Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. <i>Lancet Regional Health - Europe</i> , The, 2021, 1, 100013.	3.0	66
17	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , 2021, 27, 717-726.	15.2	838
18	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. <i>Cell</i> , 2021, 184, 1171-1187.e20.	13.5	541

#	ARTICLE	IF	CITATIONS
19	Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. <i>Nature</i> , 2021, 593, 136-141.	13.7	648
20	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , 2021, 184, 2332-2347.e16.	13.5	784
21	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021, 596, 103-108.	13.7	222
22	Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. <i>Cell Reports</i> , 2021, 35, 109292.	2.9	375
23	Tackling COVID-19 with neutralizing monoclonal antibodies. <i>Cell</i> , 2021, 184, 3086-3108.	13.5	309
24	Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. <i>Nature</i> , 2021, 595, 707-712.	13.7	363
25	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. <i>Science</i> , 2021, 373, 648-654.	6.0	385
26	After the pandemic: perspectives on the future trajectory of COVID-19. <i>Nature</i> , 2021, 596, 495-504.	13.7	260
27	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , 2021, 597, 103-108.	13.7	220
28	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. <i>Nature</i> , 2021, 597, 97-102.	13.7	385
29	Discovery and Characterization of Spike N-Terminal Domain-Binding Aptamers for Rapid SARS-CoV-2 Detection. <i>Angewandte Chemie</i> , 2021, 133, 21381-21385.	1.6	14
30	Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. <i>Nature</i> , 2021, 598, 342-347.	13.7	230
31	Discovery and Characterization of Spike N-Terminal Domain-Binding Aptamers for Rapid SARS-CoV-2 Detection. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 21211-21215.	7.2	62
32	Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	20
33	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. <i>Nature</i> , 2021, 599, 114-119.	13.7	1,041
34	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16.	13.5	131
35	Broad betacoronavirus neutralization by a stem helix-specific human antibody. <i>Science</i> , 2021, 373, 1109-1116.	6.0	262
36	Exceptionally potent human monoclonal antibodies are effective for prophylaxis and treatment of tetanus in mice. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	8

#	ARTICLE	IF	CITATIONS
37	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. <i>Science</i> , 2021, 374, 1621-1626.	6.0	232
38	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. <i>Cell</i> , 2020, 183, 1024-1042.e21.	13.5	1,195
39	AncesTree: An interactive immunoglobulin lineage tree visualizer. <i>PLoS Computational Biology</i> , 2020, 16, e1007731.	1.5	18
40	Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. <i>Nature</i> , 2020, 588, 485-490.	13.7	95
41	A combination of two human monoclonal antibodies cures symptomatic rabies. <i>EMBO Molecular Medicine</i> , 2020, 12, e12628.	3.3	26
42	Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 942-949.	3.6	153
43	A perspective on potential antibody-dependent enhancement of SARS-CoV-2. <i>Nature</i> , 2020, 584, 353-363.	13.7	413
44	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. <i>Science</i> , 2020, 370, 950-957.	6.0	504
45	Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. <i>Nature</i> , 2020, 583, 290-295.	13.7	1,695
46	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020, 28, 475-485.e5.	5.1	380
47	Capsid protein structure in Zika virus reveals the flavivirus assembly process. <i>Nature Communications</i> , 2020, 11, 895.	5.8	85
48	Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein. <i>Nature Communications</i> , 2020, 11, 596.	5.8	28
49	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 2020, , 3606354.	0.4	16
50	AncesTree: An interactive immunoglobulin lineage tree visualizer. , 2020, 16, e1007731.		0
51	AncesTree: An interactive immunoglobulin lineage tree visualizer. , 2020, 16, e1007731.		0
52	AncesTree: An interactive immunoglobulin lineage tree visualizer. , 2020, 16, e1007731.		0
53	AncesTree: An interactive immunoglobulin lineage tree visualizer. , 2020, 16, e1007731.		0
54	Alternative conformations of a major antigenic site on RSV F. <i>PLoS Pathogens</i> , 2019, 15, e1007944.	2.1	29

#	ARTICLE	IF	CITATIONS
55	Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. <i>Cell Host and Microbe</i> , 2019, 26, 623-637.e8.	5.1	56
56	Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset. <i>Antiviral Research</i> , 2019, 163, 70-74.	1.9	8
57	Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. <i>Cell</i> , 2019, 176, 1026-1039.e15.	13.5	558
58	Persistent Antibody Clonotypes Dominate the Serum Response to Influenza over Multiple Years and Repeated Vaccinations. <i>Cell Host and Microbe</i> , 2019, 25, 367-376.e5.	5.1	93
59	Comparison of Four Serological Methods and Two Reverse Transcription-PCR Assays for Diagnosis and Surveillance of Zika Virus Infection. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	58
60	Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12265-12270.	3.3	70
61	Influenza hemagglutinin membrane anchor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10112-10117.	3.3	115
62	Therapeutic Administration of Broadly Neutralizing FI6 Antibody Reveals Lack of Interaction Between Human IgG1 and Fc Receptors. <i>Frontiers in Immunology</i> , 2018, 9, 865.	2.2	19
63	Tackling influenza with broadly neutralizing antibodies. <i>Current Opinion in Virology</i> , 2017, 24, 60-69.	2.6	121
64	Protection of calves by a prefusion-stabilized bovine RSV F vaccine. <i>Npj Vaccines</i> , 2017, 2, 7.	2.9	38
65	A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential. <i>Cell</i> , 2017, 171, 229-241.e15.	13.5	118
66	Antibody-based assay discriminates Zika virus infection from other flaviviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8384-8389.	3.3	161
67	Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant <i>Klebsiella pneumoniae</i> . <i>Nature Communications</i> , 2017, 8, 1991.	5.8	70
68	Anti-LPS antibodies protect against <i>Klebsiella pneumoniae</i> by empowering neutrophil-mediated clearance without neutralizing TLR4. <i>JCI Insight</i> , 2017, 2, .	2.3	29
69	Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis. <i>EMBO Molecular Medicine</i> , 2016, 8, 407-421.	3.3	73
70	Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. <i>Science</i> , 2016, 353, 823-826.	6.0	675
71	Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes. <i>Cell</i> , 2016, 166, 596-608.	13.5	320
72	Platelet-derived growth factor- $\alpha$ receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer. <i>Nature Microbiology</i> , 2016, 1, 16082.	5.9	170

#	ARTICLE	IF	CITATIONS
73	Antibody-guided vaccine design: identification of protective epitopes. <i>Current Opinion in Immunology</i> , 2016, 41, 62-67.	2.4	53
74	Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. <i>Science</i> , 2016, 351, 1339-1342.	6.0	370
75	SARS-like WIV1-CoV poised for human emergence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 3048-3053.	3.3	373
76	A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens. <i>Nature</i> , 2016, 529, 105-109.	13.7	140
77	Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. <i>Nature Communications</i> , 2015, 6, 7375.	5.8	74
78	Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9430-9435.	3.3	38
79	Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 10473-10478.	3.3	198
80	Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 17965-17970.	3.3	116
81	Rapid development of broadly influenza neutralizing antibodies through redundant mutations. <i>Nature</i> , 2014, 516, 418-422.	13.7	300
82	Efficient Methods To Isolate Human Monoclonal Antibodies from Memory B Cells and Plasma Cells. <i>Microbiology Spectrum</i> , 2014, 2, .	1.2	39
83	Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. <i>Nature</i> , 2013, 501, 439-443.	13.7	220
84	Broadly Neutralizing Antiviral Antibodies. <i>Annual Review of Immunology</i> , 2013, 31, 705-742.	9.5	447
85	A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins. <i>Science</i> , 2011, 333, 850-856.	6.0	1,092
86	Escape from Human Monoclonal Antibody Neutralization Affects In Vitro and In Vivo Fitness of Severe Acute Respiratory Syndrome Coronavirus. <i>Journal of Infectious Diseases</i> , 2010, 201, 946-955.	1.9	88
87	Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41. <i>PLoS Pathogens</i> , 2010, 6, e1001195.	2.1	82
88	Clonal dissection of the human memory B cell repertoire following infection and vaccination. <i>European Journal of Immunology</i> , 2009, 39, 1260-1270.	1.6	200
89	Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge. <i>Journal of Virology</i> , 2008, 82, 3220-3235.	1.5	144
90	Human monoclonal antibodies by immortalization of memory B cells. <i>Current Opinion in Biotechnology</i> , 2007, 18, 523-528.	3.3	89

#	ARTICLE	IF	CITATIONS
91	Efficient Methods To Isolate Human Monoclonal Antibodies from Memory B Cells and Plasma Cells. , 0, , 129-139.		1
92	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 0, , .	13.7	101